JP2015529194A - ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ - Google Patents

ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ Download PDF

Info

Publication number
JP2015529194A
JP2015529194A JP2015527558A JP2015527558A JP2015529194A JP 2015529194 A JP2015529194 A JP 2015529194A JP 2015527558 A JP2015527558 A JP 2015527558A JP 2015527558 A JP2015527558 A JP 2015527558A JP 2015529194 A JP2015529194 A JP 2015529194A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound
group
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015527558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529194A5 (enExample
Inventor
キャポニグロ，ジョルダーノ
ヒュアン，シジョン
レハール，ジョゼフ
ワン，フイ−キン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2015529194A publication Critical patent/JP2015529194A/ja
Publication of JP2015529194A5 publication Critical patent/JP2015529194A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015527558A 2012-08-16 2013-08-14 ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ Withdrawn JP2015529194A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261683790P 2012-08-16 2012-08-16
US61/683,790 2012-08-16
PCT/US2013/054848 WO2014028566A1 (en) 2012-08-16 2013-08-14 Combination of pi3k inhibitor and c-met inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017201774A Division JP6644042B2 (ja) 2012-08-16 2017-10-18 ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ

Publications (2)

Publication Number Publication Date
JP2015529194A true JP2015529194A (ja) 2015-10-05
JP2015529194A5 JP2015529194A5 (enExample) 2016-09-29

Family

ID=49004065

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015527558A Withdrawn JP2015529194A (ja) 2012-08-16 2013-08-14 ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ
JP2017201774A Expired - Fee Related JP6644042B2 (ja) 2012-08-16 2017-10-18 ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ
JP2020000928A Expired - Fee Related JP6970217B2 (ja) 2012-08-16 2020-01-07 ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017201774A Expired - Fee Related JP6644042B2 (ja) 2012-08-16 2017-10-18 ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ
JP2020000928A Expired - Fee Related JP6970217B2 (ja) 2012-08-16 2020-01-07 ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ

Country Status (14)

Country Link
US (5) US20150216870A1 (enExample)
EP (1) EP2885003B1 (enExample)
JP (3) JP2015529194A (enExample)
KR (2) KR102245985B1 (enExample)
CN (1) CN105050623B (enExample)
AU (4) AU2013302702A1 (enExample)
BR (1) BR112015002528A2 (enExample)
CA (1) CA2879704A1 (enExample)
ES (1) ES2901712T3 (enExample)
HK (1) HK1211476A1 (enExample)
IN (1) IN2015DN00528A (enExample)
MX (1) MX369518B (enExample)
RU (1) RU2705095C2 (enExample)
WO (1) WO2014028566A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
JP2016522247A (ja) * 2013-06-18 2016-07-28 ノバルティス アーゲー 組合せ医薬
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
SG10201900648SA (en) 2014-07-25 2019-02-27 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
EP3229803B1 (en) 2014-12-12 2020-01-29 Massachusetts General Hospital Treatment of breast cancer brain metastases
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
CN115023229A (zh) * 2019-12-20 2022-09-06 里科瑞尔姆Ip控股有限责任公司 组合

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540599A (ja) * 2005-05-20 2008-11-20 ノバルティス アクチエンゲゼルシャフト 脂質キナーゼ阻害剤としてのイミダゾキノリン
JP2011527703A (ja) * 2008-07-11 2011-11-04 ノバルティス アーゲー （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物
WO2012047775A1 (en) * 2010-10-04 2012-04-12 Novartis Ag Pharmaceutical combinations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
GEP20125658B (en) * 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
RU2478387C2 (ru) * 2007-02-20 2013-04-10 Новартис Аг ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
BRPI0908049A2 (pt) * 2008-03-05 2015-08-11 Novartis Ag Uso de derivados de pririmidina para o tratamento de doenças dependentes de egfr ou de doenças que possuem resistência adquirida a agentes que são direcionados aos membros da família de egfr
SI2300455T1 (sl) * 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100267742A1 (en) * 2009-04-17 2010-10-21 Rush University Medical Center Combination targeted therapy for lung cancer
BR112013009624A2 (pt) 2010-11-08 2016-07-12 Novartis Ag uso de derivados de 2-carboxamida cicloamino ureia no tratamento de doenças dependemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfr

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540599A (ja) * 2005-05-20 2008-11-20 ノバルティス アクチエンゲゼルシャフト 脂質キナーゼ阻害剤としてのイミダゾキノリン
JP2011527703A (ja) * 2008-07-11 2011-11-04 ノバルティス アーゲー （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物
WO2012047775A1 (en) * 2010-10-04 2012-04-12 Novartis Ag Pharmaceutical combinations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUA,C.G. ET AL.: ""SIGNATURES OF DRUG SENSITIVITY IN NONSMALL CELL LUNG CANCER"", INT. J. PROTEOMICS, vol. Vol.2011，Article ID 215496, JPN5015009013, 1 January 2011 (2011-01-01), pages 1 - 13, ISSN: 0003540405 *

Also Published As

Publication number Publication date
CN105050623B (zh) 2018-06-12
MX369518B (es) 2019-11-11
AU2018201725A1 (en) 2018-04-05
US20200253980A1 (en) 2020-08-13
JP2018035188A (ja) 2018-03-08
RU2705095C2 (ru) 2019-11-05
EP2885003A1 (en) 2015-06-24
WO2014028566A1 (en) 2014-02-20
US20190083500A1 (en) 2019-03-21
US20220280523A1 (en) 2022-09-08
AU2013302702A1 (en) 2015-02-19
EP2885003B1 (en) 2021-09-29
IN2015DN00528A (enExample) 2015-06-26
JP2020079243A (ja) 2020-05-28
KR102245985B1 (ko) 2021-04-30
MX2015002005A (es) 2015-10-08
CA2879704A1 (en) 2014-02-20
US20150216870A1 (en) 2015-08-06
CN105050623A (zh) 2015-11-11
JP6644042B2 (ja) 2020-02-12
JP6970217B2 (ja) 2021-11-24
KR20210049187A (ko) 2021-05-04
AU2016238903A1 (en) 2016-10-27
ES2901712T3 (es) 2022-03-23
RU2015108755A (ru) 2016-10-10
AU2019226212A1 (en) 2019-09-26
KR20150043328A (ko) 2015-04-22
BR112015002528A2 (pt) 2018-05-22
AU2019226212B2 (en) 2020-05-14
US20190350935A1 (en) 2019-11-21
HK1211476A1 (en) 2016-05-27

Similar Documents

Publication Publication Date Title
JP6970217B2 (ja) ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ
US20200246338A1 (en) Combination therapy
JP6855243B2 (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
JP6479812B2 (ja) 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
AU2012333092B2 (en) Synergistic combinations of PI3K- and MEK-inhibitors
US20160129003A1 (en) Pharmaceutical Combinations
JP2014532647A (ja) 消化管間質腫瘍を治療する方法
RU2739992C2 (ru) Композиции апилимода и способы их применения в лечении колоректального рака
JP2019511526A (ja) がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
CN120379663A (zh) Dcc-3116和mapkap路径抑制剂组合用于治疗病症
CN119013026A (zh) 用于治疗癌症的包含gdc-6036和gdc-0077的组合疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170914

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20171114